Pemafibrate

CAS No. 848259-27-8

Pemafibrate( K-877 )

Catalog No. M16159 CAS No. 848259-27-8

A highly potent, specific PPARα agonist with EC50 of 1 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 111 Get Quote
10MG 170 Get Quote
25MG 332 Get Quote
50MG 488 Get Quote
100MG 696 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Pemafibrate
  • Note
    Research use only, not for human use.
  • Brief Description
    A highly potent, specific PPARα agonist with EC50 of 1 nM.
  • Description
    A highly potent, specific PPARα agonist with EC50 of 1 nM; displays >2,000-fold selectivity for PPARα over others subtypes in a CHO cell-based transactivation assay; upregulates the expression of several fatty acid β-oxidative genes in human hepatocytes and the mouse liver; significantly induces the expression of clinically beneficial target genes (VLDLR, FGF21, ABCA1, MBL2, ENPEP) in human hepatocytes.Dyslipidemia Approved.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    K-877
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    PPAR
  • Recptor
    PPAR
  • Research Area
    Cardiovascular Disease
  • Indication
    Dyslipidemia

Chemical Information

  • CAS Number
    848259-27-8
  • Formula Weight
    490.5476
  • Molecular Formula
    C28H30N2O6
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO
  • SMILES
    CC[C@@H](OC1=CC=CC(CN(C2=NC3=CC=CC=C3O2)CCCOC4=CC=C(OC)C=C4)=C1)C(O)=O
  • Chemical Name
    Butanoic acid, 2-[3-[[2-benzoxazolyl[3-(4-methoxyphenoxy)propyl]amino]methyl]phenoxy]-, (2R)-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Ishibashi S, et al. Atherosclerosis. 2016 Jun;249:36-43. 2. Yamazaki Y, et al. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4689-93. 3. Raza-Iqbal S, et al. J Atheroscler Thromb. 2015 Aug 26;22(8):754-72.
molnova catalog
related products
  • SR 16832

    SR 16832 is a dual-site PPARγ inhibitor. It also inhibits the binding of endogenous ligands and transcriptional activity of PPARγ, more effectively than the orthosteric covalent antagonist GW 9662 and T 0070907.

  • LY518674

    LY518674 decreases triglycerides and increases HDL-C and is used for the treatment of atherosclerosis.

  • Troglitazone

    A PPARγ activator that has antidiabetic, anti-tumor and anti-inflammatory activities.